Latham & Watkins Advises Unnatural Products in Sale to argenx for Up to US$1.15 Billion

Argenx (ARGX) agreed to acquire Unnatural Products (UNP) for up to $1.15B, combining UNP's peptide discovery platform with Argenx's immunology expertise. The deal includes $550M upfront and $595M in milestones. Argenx shares rose 5% on Euronext and 4% on Nasdaq following the announcement. Argenx's Vyvgart franchise reported $4.534B in net sales for 2026's first nine months, up 58% year-over-year.

argenx (ARGX) will acquire Unnatural Products (UNP) for up to $1.15bn, including $550m upfront. The deal adds macrocyclic peptide capabilities to argenx's immunology portfolio. UNP's team will continue operations in Santa Cruz, California, post-acquisition. The transaction is expected to close by year-end.

Argenx acquires Unnatural Products (UNP) for $550M upfront, gaining oral peptide drug capabilities. UNP's macrocyclic peptides resist digestion, enabling oral administration. Argenx's Vyvgart had $4.5B sales in 2026, up 58.1%. The deal complements Argenx's antibody expertise and competes with big pharma in immunology. UNP could receive up to $595M in milestones.

argenx to acquire Unnatural Products for up to $1.15B, combining peptide and antibody tech. J&J's prostate cancer combo shows early promise. Janux's T-cell engager targets autoimmune disease with phase 1 results.

argenx acquires Unnatural Products for up to $1.15B, including $550M upfront, to expand its drug development capabilities with macrocyclic peptide technology. The deal adds oral and long-acting medicine potential. Unnatural Products will continue operating from Santa Cruz.

Argenx will acquire Unnatural Products for $550 million upfront, with up to $595 million in milestones, totaling $1.15 billion. The deal expands Argenx's immunology pipeline with oral peptide drugs. Both boards approved the transaction, expected to close by year-end. Argenx already holds a minority stake in Unnatural Products, a California-based company designing macrocyclic peptides.